FDA has approved asparaginase erwinia chrysanthemi (recombinant) for leukaemia and lymphoma

Share This Post

August 2021: The Food and Drug Administration has approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as part of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adults and children aged one month and up who have developed hypersensitivity to E. coli-derived as

The efficacy of JZP458-201 (NCT04145531), an open-label, multi-cohort, multicenter trial in 102 patients with ALL or LBL who had hypersensitivity to E. coli-derived asparaginase as part of a multi-agent chemotherapy regimen, was examined. The average age was ten years, with a range of one to twenty-four years. Rylaze was administered intramuscularly in varied dosages to the patients.

You may like to read : Cancer treatment in India

The achievement and maintenance of nadir serum asparaginase activity (NSAA) above the level of 0.1 U/mL was the primary effectiveness outcome measure. Modeling and simulations revealed that with a dosage of 25 mg/m2 injected intramuscularly every 48 hours, 93.6 percent of patients maintained an NSAA of less than 0.1 U/mL 48 hours following a dose of Rylaze (95 percent CI: 92.6 percent , 94.6 percent ).

Abnormal liver tests, nausea, musculoskeletal pain, exhaustion, infection, headache, pyrexia, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia were the most prevalent side effects (incidence > 20%).

The suggested dosage of Rylaze when replacing a long-acting asparaginase product is 25 mg/m2 taken intramuscularly every 48 hours for the needed length of asparaginase activity.


Reference: https://www.fda.gov/

Check details here.


Take second opinion on leukemia treatment

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه
Start chat
Need help with cancer treatment?
Scan the code
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy